What do systematic reviews say?

PDEI vs placebo

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  11 studies · 4293 participants
  Low

PDEI plus alpha‐blocker vs PDEI alone

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 40 participants
  Low

PDEI plus alpha‐blocker vs PDEI alone

The review found no eligible studies for this question.

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

PDEI plus alpha‐blocker vs PDEI alone

The review found no eligible studies for this question.

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

PDEI + 5‐ARI vs 5‐ARI alone

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 695 participants
  Moderate
• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 695 participants
  Moderate

PDEI + 5‐ARI vs 5‐ARI alone

The review found no eligible studies for this question.

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

PDEI + 5‐ARI vs 5‐ARI alone

The review found no eligible studies for this question.

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  RR 1.07 [0.84, 1.36]
  1 study · 695 participants
  Low

PDEI vs placebo

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 3646 participants
  Low

PDEI vs placebo

PDEI may leads to higher adverse events compared with placebo (low certainty).

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  RR 1.42 [1.21, 1.67]
  11 studies · 4386 participants
  Low

PDEI vs alpha‐blocker

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 933 participants
  Moderate

PDEI vs alpha‐blocker

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 550 participants
  Low

PDEI vs alpha‐blocker

PDEI showed no clear difference in adverse events compared with alpha‐blockers (low certainty).

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  RR 1.35 [0.8, 2.3]
  4 studies · 786 participants
  Low

PDEI plus alpha‐blocker vs alpha‐blocker

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 193 participants
  Low

PDEI plus alpha‐blocker vs alpha‐blocker

The review found no eligible studies for this question.

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

PDEI plus alpha‐blocker vs alpha‐blocker

PDEI plus alpha‐blocker probably leads to higher adverse effects compared with alpha‐blockers alone (moderate certainty).

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  RR 2.81 [1.53, 5.17]
  4 studies · 194 participants
  Moderate